Cat. No. 1510
Alternative Name: OKY 046
Chemical Name: (2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]-2-propenoic acid hydrochloride
Biological ActivityPotent and selective inhibitor of thromboxane (TXA2) synthetase (IC50 = 4 nM). Does not inhibit prostacyclin (PGI2) synthetase, cyclooxygenase or PGE2 isomerase (IC50 > 1 mM). Inhibits platelet aggregation in vitro and arachidonate-induced arterial contraction in vivo.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Naito et al (1983) Effects of thromboxane synthetase inhibitors on aggregation of rabbit platelets. Eur.J.Pharmacol. 91 41. PMID: 6413227.
Hiraku et al (1986) Pharmacological studies on the TXA2 synthetase inhibitor (E)-3-[p-(1H-imidazol-1ylmethyl)phenyl]-2-propenoic acid (OKY-046). Jpn.J.Pharmacol. 41 393. PMID: 3093741.
Shinagawa et al (2000) Participation of thromboxane A2 in the cough response in guinea-pigs: antitussive effect of ozagrel. Br.J.Pharmacol. 131 266. PMID: 10991919.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Ozagrel hydrochloride, supplier, Selective, thromboxane, A2, synthetase, inhibitors, Thromboxane, TP, Prostanoid, Synthases, Synthetases, prostaglandins, prostacyclins, eicosanoids, OKY046
Find multiple products by catalog number
New Products in this Area
GPR35 agonist; more potent than zaprinast (Cat. No. 0947)H2L 5765834
LPA1,3,5 antagonistCYM 50308
Potent and selective S1P4 agonistH2L5186303
Potent and selective LPA2 receptor antagonistMEDICA 16
FFA1 (GPR40) agonist. Also inhibits ATP citrate lyaseBX 471
Potent, selective CCR1 antagonistPF 04418948
Potent and selective EP2 receptor antagonistLatanoprost
FP prostaglandin receptor agonist; also exhibits agonist activity at EP1 and EP3 receptorsGRI 977143
Selective LPA2 receptor non-lipid agonistCYM 50260
Potent and selective S1P4 agonistG-36
Selective GPR30 antagonistStrontium chloride
Calcium sensing receptor (CaSR) agonistCS 2100
Selective S1P1 agonistSMANT hydrochloride
Inhibits Smoothened (Smo) accumulationTUG 891
Potent and selective GPR120 agonist
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.